We want to connect, learn from and work with you.

Our Partners

Our Founders


EBMT (formerly known as The European Society for Blood and Marrow Transplantation) is a collaborative peer network of professionals working, in centres and as individuals, in the field of clinical bone marrow transplantation and cellular therapy. Together, they make up the membership of the organisation. EBMT’s aim is to be the connection between patients, scientific community and other stakeholders to anticipate the future of these fields as well as to save the lives of patients with blood cancers and other life-threatening diseases.


The European Hematology Association (EHA) promotes excellence in patient care, research, and education in hematology. We serve medical professionals, researchers, and scientists with an active interest in hematology. We are proud to be the largest European-based organization connecting hematologists worldwide to support career development and research, harmonize hematology education, and advocate for hematologists and hematology.

The EHA and the EBMT, the two leading European societies in the field of hematology and stem cell transplantation, announced a strategic partnership to empower Europe to become a global leader in the cellular therapy field for hematological diseases, joining forces and bringing their collective resources and expertise to the newly founded GoCART coalition. 

Advancing the field of cell and gene-based therapies requires progress on multiple fronts, including creating a pre- and post-authorization registry to monitor product safety and efficacy; harmonizing data collection, center qualification and educational requirements, and overcoming barriers in regulations designed for more traditional pharmaceutical products. To address such a wide range of complex issues, there is a need for strong collaboration amongst all relevant stakeholders.  

The network is open to any relevant stakeholder, including patient representatives, health care professionals, pharmaceutical companies, health authorities, health technology assessment bodies and reimbursement agencies, European and national medical organizations and registry holders.  

The first concrete activities underway include the development of a joint educational program, a multi-stakeholder review of EBMT’s cellular therapy data collection form, and harmonization of existing site qualification schemes to reduce inspection burden for hospitals. These are some of the areas that show the potential of this coalition to advance the field of gene and cellular therapies in Europe in the interests of our patients.